In multiple myeloma (MM), enhanced proliferation and resistance to apoptosis account for expansion of the malignant clone. 1, 2 Previous investigations have demonstrated alteration of the ERK, 3 jun kinase, 4 STAT, 5 and AKT kinase 6 signaling cascades in MM cells and implicated the pathways in clonal expansion. These studies, however, were mainly investigations in cell lines, and it is unclear whether the observations can be extrapolated to tumors in patients. We therefore used immunohistochemical (IHC) staining to test activation of AKT in situ in MM cells of patients. AKT is activated downstream of phosphatidylinositol 3-kinase (PI3-kinase) by translocation to the cell membrane 7 and phosphorylation at Ser and Thr residues. 8 Its activity is inhibited by the tumor suppressor PTEN phosphatase. Our IHC assay with a phosphospecific anti-AKT antibody confirmed frequent AKT activation in MM cells of patients with stage III disease. Further evaluation of 2 MM cell cultures, recently explanted from patients, indicated that AKT activation may play a role in MM cell expansion.
Introduction
In multiple myeloma (MM), enhanced proliferation and resistance to apoptosis account for expansion of the malignant clone. 1, 2 Previous investigations have demonstrated alteration of the ERK, 3 jun kinase, 4 STAT, 5 and AKT kinase 6 signaling cascades in MM cells and implicated the pathways in clonal expansion. These studies, however, were mainly investigations in cell lines, and it is unclear whether the observations can be extrapolated to tumors in patients. We therefore used immunohistochemical (IHC) staining to test activation of AKT in situ in MM cells of patients. AKT is activated downstream of phosphatidylinositol 3-kinase (PI3-kinase) by translocation to the cell membrane 7 and phosphorylation at Ser and Thr residues. 8 Its activity is inhibited by the tumor suppressor PTEN phosphatase. Our IHC assay with a phosphospecific anti-AKT antibody confirmed frequent AKT activation in MM cells of patients with stage III disease. Further evaluation of 2 MM cell cultures, recently explanted from patients, indicated that AKT activation may play a role in MM cell expansion.
Study design

Myeloma cells
Bone marrow (BM) cells from one MM patient and peripheral blood from a second with plasma cell leukemia were separated by an immunoabsorption column to isolate high CD38-expressing cells (as described by Tu et al 6 ). The separated cells consisted of more than 98% plasma cells by light microscopy. These cells were cultured in vitro without growth factors in complete RPMI media. After 1 week, the cultures were composed of 100% malignant plasma cells that began to slowly proliferate and have been maintained in culture for at least 4 months. These cells morphologically resemble plasma cells and express high levels of membrane CD38 and monoclonal cytoplasmic light chain. Their doubling time is approximately 60 hours.
Transient transfections and flow cytometry
The kinase-inactive AKT construct, HA-AKT(K179M), functions as a dominant negative inhibitor of endogenous AKT. 9 It was cloned into the enhanced green fluorescence protein (EGFP)-expressing vector, pEGFP-C2 (Clontech) at HindIII/SmaI sites. Myeloma cells were transiently transfected with HA-AKT(K179M) or empty pEGFP-C2 vector by electroporation (250 V for 25 ms). At 24 hours after transfection, viable cells were stained with the DNA dye Hoechst at 2.5 g/mL for 20 minutes and cell cycle distribution was determined by first gating on EGFP-fluorescing cells. EGFP fluorescence demonstrated 8% to 10% transfection efficiency for both HA-AKT(K179M) and empty vector.
Patient population
Archival BM biopsies obtained from patients at Kaiser Permanente Hospital (Woodland Hills, CA) were immunostained for phosphorylated AKT. Biopsies were obtained at the time of diagnosis between 1990 and 1999 and clinically staged by the Durie-Salmon system. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM were diagnosed in patients as previously described. 10, 11 
IHC staining
Immunohistochemical staining was performed on Bouin-fixed biopsies as previously reported, 12 using a diaminobenzadine-based detection method. The phosphospecific anti-AKT antibody, obtained from Bioscience (catalog no. 44-622; Princeton, NJ), which recognizes phosphorylated AKT, was used as the primary antibody. Negative controls, where the primary anti-AKT antibody was For personal use only. on August 16, 2017. by guest www.bloodjournal.org From omitted, were uniformly negative for immunostaining. In preabsorption studies, the phosphospecific anti-AKT antibody was preadsorbed with 1 to 2 g/mL of either phosphorylatedAKT peptide (sequence ϭ Ac-C(Ahx)KHFPQF(pS)YSAS-NH 2 or nonphosphorylated peptide (sequence ϭ Ac-C(Ahx)KHFPQFSYSAS-NH 2 ). (Single-letter amino acid codes used.) Frequency of phospho-AKT expression was determined by counting at least 250 plasma cells from 3 different areas in BMs from patients with myeloma. For patients with MGUS, only 50 to 100 plasma cells were enumerated.
Western blot analysis
Western blot analysis was performed as previously described. 13 Densitometric analysis was used to determine the median effective dose (ED 50 ) for wortmannin (drug dose inhibiting phosphorylation by 50%).
Statistics
The t test was used to determine significance.
Results and discussion
AKT activation in myeloma BM biopsies
The AKT kinase is activated by phosphorylation at Ser473. We thus tested activation of AKT in myeloma marrow by IHC using a phosphospecific anti-AKT antibody that only detects AKT when it is phosphorylated at Ser473. As shown in Figure 1 , the phospho-AKT antibody readily stained myeloma plasma cells. Immunostaining was present in a cell membrane-specific pattern, consistent with the known subcellular locale when AKT becomes activated. Of note, staining was specific for myeloma tumor cells because nonmalignant hematopoietic cells in these same biopsies were negative. In 3 of the BM samples, immunostaining of MM cells was abrogated when the antibody was absorbed with phosphorylated, but not nonphosphorylated, AKT peptide, attesting to the specificity of immunostaining. Examples of peptide preabsorption in one BM sample are shown in panels B and C of Figure 1 .
The percent of malignant plasma cells positively stained in these biopsies was significantly (P Ͻ .05) higher in Durie-Salmon stage III patients than in stage I ( Figure 1E ). Frequency of staining in stage I disease was comparable to that of indolent MM. No plasma cell immunostaining was detected in marrows from 10 patients with MGUS ( Figure 1E ). Although the degree of plasma cell infiltration of these MGUS marrows was low (mean 2%), the plasma cells were easily identified and were clearly nonreactive with the antibody (Figure 1D , arrows).
Inhibition of AKT activation inhibits MM cell growth
We next studied MM cell populations from 2 patients; the cells were successfully cultured over a 4-month period. Immunoblotting demonstrated constitutive phosphorylation of AKT which, in one case (UCLA no. 1), was sensitive to the PI3-kinase inhibitor, wortmannin (Figure 2A) . Wortmannin also induced a cytoreductive effect on these MM cells and this correlated with its ability to inhibit AKT phosphorylation. The concentration required for 50% inhibition of cell recovery (LD 50 ) after 72 hours was 0.02 M for UCLA no. 1 cells, whereas the ED 50 for inhibition of AKT activation was 0.01 M. Constitutive AKT phosphorylation in the UCLA no. 2 cell line was more resistant to wortmannin with an inhibition detected only at wortmannin concentrations more than 0.1 M. We also transiently transfected these MM cells with a plasmid expressing a dominant negative AKT gene (K179M) fused to the EGFP gene, or (as a control) the empty vector expressing only EGFP, and then performed flow cytometry for cell cycle analysis (Hoechst staining) on EGFP-gated cells. The expression of EGFP from both plasmids in both MM cell populations was comparable (7%-10%) after transfection. As shown in representative experiments ( Figure 2B) , expression of the dominant negative K179M in UCLA no. 1 MM cells resulted in a decreased number of cells in S phase (10% versus 34% in control cells) and increase in apoptosis (16% versus 0%) as shown by a sub-G 1 peak. In UCLA no. 2 cells, expression of the dominant negative AKT resulted in a decrease in S-phase distribution (4% versus 17%). Cell cycle distribution in cells transfected with the control EGFP plasmid were not altered compared to nontransfected cells (not shown). The 2 experiments shown in Figure 2B were repeated twice with identical results.
In this study, AKT was frequently activated in MM cells and the frequency of activation correlated with disease activity, being significantly greater in stage III disease compared to stage I or indolent MM and being undetected in MGUS. We 6 and others 14 have shown that interleukin 6 and insulinlike growth factor 1 can activate AKT in myeloma cells. Thus, the detected AKT activation in MM marrow may have been due to cytokine stimulation in situ. However, as shown in 2 MM cell populations in vitro, constitutive activation may exist. This could be due to autocrine cytokine stimulation, loss-of-function PTEN mutations, or to gain-offunction mutations in AKT or PI3-kinase. Hyun et al 14 found PTEN mutations in some human myeloma cell lines. Thus, PTEN mutations may occur in patients with myeloma and could explain heightened AKT activation.
When the AKT pathway was paralyzed by transient transfection with a dominant negative AKT construct, a decrease in S-phase distribution (and increase in apoptosis in one case) was found in Hoechst-stained cells. This is consistent with the work of Hyun and coworkers 14 who described an inhibitory effect of PTEN transfection in MM cells concurrent with a decrease in AKT activation.
In summary, these results indicate that activation of AKT occurs in MM plasma cells. Because of its central location, activating diverse downstream proliferative and antiapoptotic pathways, AKT is a promising target for future molecular-based therapy. In addition, the frequent activation in myeloma tumor cells compared to nonmalignant cells suggests a therapeutic window may exist in patients. BLOOD, 1 NOVEMBER 2001 ⅐ VOLUME 98, NUMBER 9 For personal use only. on August 16, 2017. by guest www.bloodjournal.org From
